NIPT and Beyond…

Tuan Tran, MD, PhD. Unit of Genetic & Genomic Medicine, Family Hospital, Da Nang

1. NIPT made simple

It is a bit of a mind-bender, isn't it? The idea that a tiny fragment floating in blood could tell you the whole story of a person seems like magic, but it’s actually a very clever bit of biological "puzzle-solving."

Here is the "baby-talk" explanation of **how we see the big picture from such tiny pieces.**

1.1.The Giant Instruction Manual

Imagine the baby’s DNA is a **giant instruction manual** with 46 chapters (the chromosomes). This manual is kept inside the "factory" (the placenta).

1.2. The Shredder

As the factory works, it constantly recycles itself. Some of the pages from that manual get shredded into **tiny confetti**. This confetti (cell-free DNA) is so small that it leaks out of the factory doors and floats away into the mother’s "river" (the bloodstream).

1.3. The Confetti Mess

When a doctor takes a blood sample, they are catching a bucket of water from that river. Inside that bucket, there are millions of pieces of confetti.

- Most of the confetti is from the **Mom’s** manual.
- A little bit of it (about 10%) is from the **Baby’s** manual.

1.4. The Super-Fast Scanner

The NIPT machine doesn't try to tape the pages back together to read them. Instead, it’s like a super-fast scanner that looks at each tiny piece of confetti and asks: **"Which chapter did you come from?"**

Because we already know what the "standard" manual looks like, the machine can recognize a scrap of paper and say, "Oh, this sentence belongs in Chapter 21!"

1.5. Counting the Scraps

This is the "aha!" moment: **NIPT is a counting game, not a reading game.**

The machine counts thousands and thousands of these scraps.

- If Chapter 21 is supposed to have 100 scraps, but the machine finds **150 scraps**, it knows there is an extra Chapter 21 (Trisomy 21).
- If it finds the right amount for every chapter, it knows the baby likely has the standard 46 chromosomes.

In Short

The fragment doesn't contain the *whole* 46 chromosomes. Each fragment is just a **single letter or word**. But by looking at millions of these tiny words and seeing which "chapters" they belong to, the computer can tell if there are too many or too few pages in the baby's book.

In summary, we don't need one big piece of DNA; we just need enough tiny pieces to see if the "pile" for one chromosome is bigger than it should be.

1.6. How to differentiate the mom's "confetti" (DNA) from the baby's "confetti" (DNA)?

To tell the difference between the mom's "confetti" and the baby's "confetti," scientists act like detectives looking for two very specific clues: Size and Signature.

i. The Size Clue (The "Shorty" Rule)

The coolest trick is that baby DNA fragments are actually shorter than mom’s DNA fragments.

- Mom’s DNA usually comes from healthy cells that lived a full life. When they break down, the fragments are like long strips of paper (around 166 "letters" long).
- Baby’s DNA (from the placenta) breaks down much more aggressively. These pieces are like tiny snippets (usually around 143 "letters" long).

The lab machine measures the length of every single piece of DNA it finds. If it's a "shorty," the computer marks it as "likely baby."

ii. The "Signature" Clue (SNPs)

Imagine Mom’s manual is printed in blue ink and Dad’s is in red ink.

- The baby is a 50/50 mix, so the baby’s "confetti" will have some red ink that the mom simply doesn't have in her own body.

Scientists look for these tiny genetic differences (called SNPs or Single Nucleotide Polymorphisms). When the machine sees a "red ink" fragment in the mom's blood, it knows for a fact: *"This belongs to the baby."*

iii. Why This Matters

By separating the baby’s scraps from the mom’s scraps, the lab can calculate the Fetal Fraction.

The Fetal Fraction: This is the percentage of the total "confetti" that belongs to the baby. Usually, it needs to be at least 4% for the test to be accurate. If there isn't enough baby confetti in the bucket, the lab can't "count" accurately and might ask for a re-draw.

iv. NOTE: Why doesn't the DNA just disappear?

Even though these fragments are tiny and "shredded," the mother’s body is constantly being flooded with new ones as the placenta grows. However, they don't stay there forever! Within hours of the baby being born and the placenta leaving the body, all that "baby confetti" vanishes from the mother's blood.

1.7. how, with this "counting" method, to figure out if the baby is a boy or a girl?

Determining the baby's sex is actually the easiest part of the "counting game" because it involves looking for a chapter that shouldn't be there for the mom at all.

i. The "Unexpected Chapter" Trick

Remember how we said the machine counts fragments to see if chapters are too big? For sex determination, it looks for the Y Chromosome.

- Mom's Manual: She has two X chromosomes. She has zero Y chapters in her "library."
- The Detection: If the lab finds *any* confetti that belongs to the Y chromosome, they know it didn't come from Mom. It must be from the baby.

Sex Chromosome



ii. How the Results Work

The computer runs a simple check:

If the machine finds...	The Result is...
Only X fragments	It's a Girl (XX).
X fragments + Y fragments	It's a Boy (XY).

iii. Why is it so accurate?

Because a woman (usually) has no Y chromosome DNA in her blood, finding even a small amount of "Y confetti" is a very strong signal. It is much easier to spot a "new" chapter (the Y) than it is to count if an existing chapter (like 21) has slightly too many pages.

iv. Is it ever wrong?

It's about 99% accurate, but there are two "oops" scenarios:

Vanishing Twin: If there was a twin brother who didn't develop early on, his "Y confetti" might still be floating in the river for a few weeks.

Transplants: If a mom has ever had a bone marrow transplant from a male donor, her blood might contain "Y confetti" that belongs to the donor, not the baby!

2. Beyond NIPT (to Invasive Diagnostic Testing)

it is fascinating that NIPT is evolving far beyond just counting chromosomes. We are moving from "Chapter Counting" to "Spell-Checking" the baby's manual.

2.1. Beyond Chromosomes: Screening for Monogenic Disorders

Standard NIPT counts whole chromosomes (like Trisomy 21). However, "Extended NIPT" or **Single-Gene NIPT (sgNIPT)** now looks for tiny spelling errors in individual genes.

This is particularly relevant for conditions like **Skeletal Dysplasias**, **Cystic Fibrosis**, and **Sickle Cell Disease**. Instead of just counting the "books," the scanner now reads specific "sentences" to see if a single letter is wrong.

2.2. NIPT and Monogenic Diabetes (MODY)

For someone interested in diabetes management, there is exciting progress in using NIPT for **Monogenic Diabetes of the Young (MODY)**.

- If a mother has a GCK or $HNF4A$ mutation, NIPT can now be used to see if the baby has inherited that specific variant.
- **Why it matters:** If a baby inherits a GCK mutation, they will likely be a normal weight. If they *don't* inherit it from a mother who has it, they are at risk for **macrosomia** (being very large at birth) because the mother's high blood sugar causes the baby to overproduce insulin.

2.3. The Future: Inborn Errors of Metabolism (IEM)

While most Inborn Errors of Metabolism (like those you've been teaching) are still diagnosed via newborn screening or amniocentesis, NIPT is starting to bridge the gap.

- **De Novo Mutations:** NIPT is becoming excellent at catching "new" mutations that neither parent has (like those causing Noonan Syndrome).
- **Relative Mutation Dosage (RMD):** Labs use high-tech "digital PCR" to see if there is a tiny imbalance in the maternal blood—for example, if there is slightly more of a "disease" version of a gene than a "healthy" one, suggesting the baby has the condition.

2.4. Comparison of NIPT Capabilities (2026)

Test Type	What it "Sees"	Common Conditions
Basic NIPT	Extra or missing "Books"	Down Syndrome, Edwards Syndrome
Microdeletion NIPT	Missing "Paragraphs"	DiGeorge Syndrome (22q11.2)
Single-Gene NIPT	Single "Typos"	Achondroplasia, Cystic Fibrosis
Metabolic Screening	Genetic Markers for IEMs	Emerging (e.g., Gaucher Disease, MMA)

Clinical Note:

While NIPT is incredibly powerful, it remains a **screening tool**. If a "typo" is found in the baby's DNA confetti, a "diagnostic" test (like amniocentesis) is still needed to confirm it by looking at the actual cells.

3. Comparative Chart & Clinical Cases

3.1: NIPT vs. Invasive Diagnostic Testing

This chart is designed to help students understand why we call NIPT a "screening" test despite its high accuracy.

Feature	NIPT (Screening)	Amniocentesis / CVS (Diagnostic)
Source	Placental cfDNA in maternal blood	Actual fetal cells (amniocytes/villi)
Procedure	Simple maternal blood draw	Ultrasound-guided needle/catheter
Risk	**Zero** risk of miscarriage	Small risk (approx. 0.1% to 0.5%)
Accuracy	>99% for T21; lower for others	**99.9% (Gold Standard)**
What it sees	Chromosome counts & specific SNPs	Full Karyotype, Microarray, & WES
Timing	10+ weeks gestation	11–13 (CVS) or 15+ (Amnio) weeks

Feature	NIPT (Screening)	Amniocentesis / CVS (Diagnostic)
Metabolic Use	Screens for inheritance of known mutations	Confirms enzyme levels and gene sequence

3.2: Clinical Case Studies

These cases illustrate how NIPT is moving into the "clinical management" phase of metabolic and diabetic care.

3.2.1. Case 1: The GCK-MODY Management Puzzle

Patient: A 32-year-old G1P0 woman with a confirmed diagnosis of **Glucokinase (GCK) Monogenic Diabetes**.

- **The Problem:** If the baby inherits the GCK mutation, its "thermostat" for blood sugar is also set higher; the baby is healthy and will have a normal birth weight. If the baby *doesn't* inherit the mutation, the mother's slightly high blood sugar will cause the baby to over-secrete insulin and become **macrosomic** (very large).
- **NIPT Application:** Single-gene NIPT (Non-Invasive Prenatal Diagnosis = NIPD) is performed at 12 weeks to check for the maternal GCK variant in the fetal DNA.
- **Clinical Management:**

  Result - Positive (Inherited): No aggressive insulin therapy for the mother; routine growth scans.

  Result - Negative (Not Inherited): Intensive insulin therapy for the mother to protect the baby **from macrosomia.**

3.2.2. Case 2: Inborn Error of Metabolism (MMA)

Patient: A couple who are both known carriers for **Methylmalonic Acidemia (MMA)**, an organic acidemia you've recently covered.

- **The Challenge:** Traditional management requires waiting until the baby is born or doing an invasive amniocentesis.
- **NIPT Application:** The lab uses **Relative Mutation Dosage (RMD)**. They count the "healthy" vs. "mutated" scraps of DNA.
- **Clinical Insight:** If NIPT shows the baby is likely affected, the clinical team can prepare for **immediate** neonatal intervention (special formula, B12 therapy) starting in the delivery room, preventing the "metabolic crash" that often occurs in the first 48 hours of life.

3.2.3. Case 3: The "Metabolic" Interference (Hypertriglyceridemia)

Patient: A 38-year-old woman with Type 2 Diabetes and high triglycerides (TG > 2.3 mmol/L) undergoing routine NIPT.

- **The Issue:** The lab returns a "No Result" or "Low Fetal Fraction" (less than 4%).
- **The Lesson for Students:** High lipid levels and maternal BMI can physically interfere with the lab's ability to see the "baby confetti."
- **Management:** Instead of jumping straight to an invasive needle, the clinician may wait 2 weeks (as the baby grows, its DNA fraction increases) and re-draw the blood once metabolic markers are better stabilized.

REFERENCES:

1. Caswell R, Snowsill T, Turner HE, Wakeling MN, Weedon MN, Knight BA, et al. Noninvasive fetal genotyping by droplet digital PCR to identify maternally inherited monogenic diabetes variants. Clin Chem. 2020;66(11):1410-9. https://pubmed.ncbi.nlm.nih.gov/32533152/
2. Qi, H., Chen, H., Zhang, Z., Gan, J., Liu, H., Yuan, X., Luo, F., Chen, J., & Shen, S. (2025). Performance and clinical implications of non-invasive prenatal testing for rare chromosomal abnormalities: A retrospective study of 94,125 cases. *Frontiers in Molecular Biosciences*, *12*, 1645223. https://doi.org/10.3389/fmolb.2025.1645223
3. Sul Lee et al. Clinical applications and advancements in noninvasive prenatal diagnosis. www.kosinmedj.org https://www.kosinmedj.org/upload/pdf/kmj-25-118.pdf
4. Hanson B, Paternoster B, Povarnitsyn N, Scotchman E, Chitty L, Chandler N. Non-invasive prenatal diagnosis (NIPD): current and emerging technologies. Extracell Vesicles Circ Nucl Acids. 2023 Feb 22;4(1):3-26. doi: 10.20517/evcna.2022.44. PMID: 39698301; PMCID: PMC11648410. https://pubmed.ncbi.nlm.nih.gov/39698301/
5. Poulton A, Hui L. Noninvasive prenatal testing: an overview. Aust Prescr 2025;48:47-53.https://doi.org/10.18773/austprescr.2025.019